Status:
RECRUITING
Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV
Lead Sponsor:
Centers for Disease Control and Prevention
Conditions:
Monkeypox
HIV Infections
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to examine the extent of mpox viral spread and immunologic markers in people with advanced HIV. Study findings will enhance knowledge of mpox pathogenesis in severely immu...
Detailed Description
Primary objective: Describe the relationship between the systemic immunologic response and the persistence and replication competence of mpox virus at rash lesions, in blood, and at mucosal sites ove...
Eligibility Criteria
Inclusion
- Age ≥18 years; AND
- HIV infection with CD4 count \< 200 cells/uL; AND
- Probable or confirmed mpox (does NOT need to be a new diagnosis); AND
- Hospitalized while symptomatic from mpox, for reasons other than (or in addition to) infection prevention and control
Exclusion
- Inability of the individual or appropriate proxy to provide informed consent.
- In the judgment of the clinical treating team, has a medical condition or other factor that might affect their ability to participate in the evaluation.
Key Trial Info
Start Date :
March 17 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06045923
Start Date
March 17 2023
End Date
October 1 2026
Last Update
March 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centers for Disease Control and Prevention
Atlanta, Georgia, United States, 30333